๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for NSCLC (Advanced Non-small Cell Lung Cancer)

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064n/a1 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: Ensartinib Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation NCT05010109NA1 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography, Echocardiography, Exercise Cardiac Stress Tโ€ฆ Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221Phase 1, Phase 298 sites๐Ÿ“ Gilbert๐Ÿ“ Duarte๐Ÿ“ Irvine Revolution Medicines, Inc. ยท Tests: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors NCT04557449Phase 1, Phase 239 sites๐Ÿ“ Los Angeles๐Ÿ“ New Haven๐Ÿ“ New Haven Pfizer ยท Tests: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: ORIENT-31 regimen, SBRT A Phase I Study of CFT8919 in Patients With Advanced NSCLC NCT06641609Phase 11 site๐Ÿ“ Hangzhou Betta Pharmaceuticals Co., Ltd. ยท Tests: Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8โ€ฆ A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Boston Taiho Oncology, Inc. ยท Tests: TAS6417, CYP Cocktail, Transporter Cocktail Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) NCT07761910Phase 21 site๐Ÿ“ Indianapolis Indiana University ยท Tests: PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762Phase 162 sites๐Ÿ“ Birmingham๐Ÿ“ Birmingham๐Ÿ“ Birmingham Seagen, a wholly owned subsidiary of Pfizer ยท Tests: PF-08046054, pembrolizumab A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites๐Ÿ“ Newport Beach๐Ÿ“ San Diego๐Ÿ“ San Francisco Bayer ยท Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer NCT07017829Phase 21 site๐Ÿ“ Buffalo Roswell Park Cancer Institute ยท Tests: Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites๐Ÿ“ Scottsdale๐Ÿ“ La Jolla๐Ÿ“ Stanford BioEclipse Therapeutics ยท Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites๐Ÿ“ London๐Ÿ“ Manchester๐Ÿ“ Southampton Cancer Research UK ยท Tests: TT-702, Anti-PD-1 and PD-L1 agent A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer NCT07659782Phase 224 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles Verastem, Inc. ยท Tests: VS-7375 A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib NCT06668103Phase 25 sites๐Ÿ“ Hefei๐Ÿ“ Harbin๐Ÿ“ Wuhan Abbisko Therapeutics Co, Ltd ยท Tests: ABSK043 in combination with Firmonertinib Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites๐Ÿ“ Sacramento๐Ÿ“ Tampa๐Ÿ“ Tampa National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Kura Oncology, Inc. ยท Tests: Darlifarnib, Cabozantinib, Adagrasib Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Stanford Obsidian Therapeutics, Inc. ยท Tests: OBX-115 AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors NCT07094113Phase 139 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Atlanta Amgen ยท Tests: AMG 410, Pembrolizumab, Panitumumab A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-1084-004/KANDLELIT-004) NCT06345729Phase 3246 sites๐Ÿ“ Bakersfield๐Ÿ“ Beverly Hills๐Ÿ“ Stamford Merck Sharp & Dohme LLC ยท Tests: Calderasib, Placebo, Pembrolizumab GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites๐Ÿ“ New York๐Ÿ“ New York๐Ÿ“ Huntersville GI Innovation, Inc. ยท Tests: GI-101, Pembrolizumab (KEYTRUDAยฎ), Lenvatinib, GI-101A A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations NCT06430437Phase 31 site๐Ÿ“ Shanghai Jiangsu HengRui Medicine Co., Ltd. ยท Tests: SHR-A1811, PD-1/PD-L1 inhibitorsใ€Pemetrexed/ Paclitaxelใ€Carboplatin/ Cisplatin Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ยฑ Bevacizumab and Definitive Concurrent Chemoradiation Therapy NCT05468242Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy, Tislelizumab ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy NCT07109531Phase 31 site๐Ÿ“ Shanghai Jiangsu Aosaikang Pharmaceutical Co., Ltd. ยท Tests: ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site๐Ÿ“ Nanchang Second Affiliated Hospital of Nanchang University ยท Tests: Vebreltinib, Furmonertinib 80mg A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) NCT05865002Phase 137 sites๐Ÿ“ Vijayawada๐Ÿ“ Visakhapatnam๐Ÿ“ Chandigarh Aurigene Discovery Technologies Limited ยท Tests: AUR107 Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG NCT06107374Phase 21 site๐Ÿ“ Iowa City CellSight Technologies, Inc. ยท Tests: [18F]F-AraG A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors NCT07300150Phase 19 sites๐Ÿ“ Boston๐Ÿ“ San Antonio๐Ÿ“ San Antonio PAQ Therapeutics, Inc. ยท Tests: PT0511, Cetuximab A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site๐Ÿ“ Taipei AP Biosciences Inc. ยท Tests: AP203, AP203
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy